IGUB20054, Fung, SGN22E-002, Urothelial Cancer, enfortumab vedotin (EV), pembrolizumabResearch Question:
How well does an experimental drug (enfortumab vedotin) work alone and with different
combinations of anticancer therapies?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This study will test an experimental drug (enfortumab vedotin) alone and with different
combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor
(CPI) that is used to treat patients with cancer of the urinary system (urothelial
cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter
or urethra. Some parts of the study will look at locally-advanced and metastatic urothelial
cancer, which means the cancer has spread to nearby tissues or to other areas of the
body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC),
which is cancer at an earlier stage that has spread into the muscle wall of the bladder.
This study will look at the side effects of enfortumab vedotin alone and with other
anticancer therapies. A side effect is a response to a drug that is not part of the
treatment effect. This study will also test if the cancer shrinks with the different
Study Reference #: IGUB20054
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search